Technical Analysis for ATNX - Athenex, Inc.
|Grade||Last Price||% Change||Price Change|
ATNX closed down 1.12 percent on Monday, October 15, 2018, on 61 percent of normal volume. The bears made the stock sink to a new 52-week low. The price action carved out a bearish shooting star candlestick pattern. That may indicate a downside reversal. Look for price to trade beneath the low of the shooting star for confirmation. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
|See historical ATNX trend table...|
|Date||Alert Name||Type||% Chg|
|Oct 15||New 52 Week Closing Low||Bearish||0.00%|
|Oct 15||Shooting Star Candlestick||Bearish||0.00%|
|Oct 15||Slingshot Bearish||Bearish Swing Setup||0.00%|
|Oct 15||Wide Range Bar||Range Expansion||0.00%|
|Oct 15||Doji - Bearish?||Reversal||0.00%|
|Oct 15||Doji - Bullish?||Reversal||0.00%|
|Oct 15||New 52 Week Low||Weakness||0.00%|
|Oct 15||Outside Day||Range Expansion||0.00%|
|Oct 15||Wide Bands||Range Expansion||0.00%|
|Oct 15||Down 3 Days in a Row||Weakness||0.00%|
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicatorsBasic chart:
Athenex, Inc. is an oncology pharmaceutical company focused on the development and commercialization of therapies for cancer diseases and supportive therapies. The Company's technology platform is organized into three categories, including Oral Absorption Platform, Src Kinase Inhibitors and Symptom Therapeutics. The Company offers Oraxol, an oral formulation of paclitaxel; Orateacan, an oral formulation of Irinotecan; Oradoxel, an oral formulation of Docetaxel, and an oral formulation of Topotecan for the treatment of various types of cancers. Its Src Kinase Inhibitors include KX-01 (KX2-391) and KX-02 (KX2-361) oncology drug candidates. The Company's Symptom Therapeutics include CQ-01, which is used for the treatment of burn pruritus and scars; CQ-R1, which is used for the treatment of an irradiation-induced dermatitis, and an intranasal Granisetron used for the treatment of chemotherapy-induced nausea/vomiting.
|Indicator||Bull Case||Neutral / Hold||Bear Case|
|Oversold / Overbought|
|Summary:||Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.|
See more ATNX news...
|52 Week High||20.9|
|52 Week Low||13.15|
|200-Day Moving Average||16.7292|
|50-Day Moving Average||16.2306|
|20-Day Moving Average||15.1905|
|10-Day Moving Average||14.26|
|Average True Range||0.6366|
|Chandelier Exit (Long, 3 ATRs )||15.1702|
|Chandelier Exit (Short, 3 ATRs )||15.0598|
|Upper Bollinger Band||17.4918|
|Lower Bollinger Band||12.8892|
|Percent B (%b)||0.07|
|MACD Signal Line||-0.6498|
|Market Cap||754.38 Million|
|Num Shares||57.1 Million|
|Price-to-Earnings (P/E) Ratio||-3.81|
|Pivot Point Level||Traditional / Classic||Fibonacci||Demark||Woodie||Camarilla|
|Resistance 4 (R4)||15.85|
|Resistance 3 (R3)||16.11||15.51||15.41|
|Resistance 2 (R2)||15.51||14.84||15.37||15.26|
|Resistance 1 (R1)||14.36||14.43||14.06||14.10||15.12|
|Support 1 (S1)||12.61||13.09||12.31||12.35||11.32|
|Support 2 (S2)||12.01||12.68||11.87||11.18|
|Support 3 (S3)||10.86||12.01||11.03|
|Support 4 (S4)||10.60|